Why Is the Overseas Registration Timeline for Dental Devices Extended?

The overseas registration cycle for dental devices is typically extended not because a single step has gone out of control, but because of the combined effect of the registration pathway, the maturity of technical documentation, target-country regulatory requirements, and the allocation of internal corporate resources.

Key Summary

The prolongation of overseas registration cycles for dental devices is usually not the result of a single step losing control, but of the combined effect of the registration pathway, technical documentation maturity, target-country regulatory requirements, and internal corporate resources. Common causes include: incorrect determination of the product risk classification leading to a pathway change, technical documentation not organized according to the target country’s format, insufficient biocompatibility, electrical safety, or performance verification evidence, inadequate justification for clinical evaluation exemption, labels and instructions for use not localized, unclear responsibilities of the local agent or authorized representative, and excessive requests for correction after submission.

Companies should first confirm whether the product falls within the regulatory scope of medical devices in the target country, and then select the registration pathway and applicant based on risk classification. Next, they should assess the reusability of existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation, and perform localized conversion for GHWP member states, Southeast Asia, the Middle East, Latin America, and other markets. The key risk-prevention measures are to lock the registration strategy early, establish a complete evidence chain, appoint a competent local agent, and reserve time for post-market maintenance and change/continuation applications. If these elements are neglected at an early stage, the registration cycle may extend from the expected 6–12 months to more than two years.

Applicable Scenarios and Core Issues

When dental device companies plan to enter overseas markets, the first issue they often encounter is not a technical problem but a loss of control over the registration timeline. At project initiation, they may plan to obtain certification in twelve months, but in reality it takes twenty months or even longer. This is very common for dental treatment units, implants, root canal treatment devices, dental restorative materials, and similar products.

The core issue is that the registration timeline is not a simple countdown clock; it is determined by the regulatory pathway, documentation quality, evidence sufficiency, and the review workload of the authority. If a company cannot accurately identify these variables, it will be continuously interrupted by requests for supplementary information, technical queries, and clinical evidence requirements.

Applicable scenarios include first entry into GHWP member state markets, expanding into Southeast Asia or the Middle East with existing CE or FDA certificates, and multinational submissions planned after domestic NMPA registration. In different scenarios, the causes of timeline extension are clearly different.

A common question from companies is why a peer obtains certification faster for the same product. The answer is usually not in any single step, but in the registration decision logic and the organization of the evidence chain.

Registration Decision Logic

Step 1: Determine regulatory scope. The first step is not to translate existing instructions for use but to determine whether the product falls under the regulatory scope of medical devices in the target country. Some dental products may be classified as ordinary consumer goods or oral care products in a given country. Different classifications lead to completely different registration pathways.

Step 2: Determine risk classification. Dental implants and bone repair materials are usually high-risk and require clinical evaluation; dental burs, mouth mirrors, and dental impression trays are generally lower-risk and may follow self-declaration or simplified registration. An incorrect risk classification will directly lead to a pathway change, and rewriting the technical documentation will naturally extend the timeline.

Step 3: Determine the applicant. Most countries require a local registrant to hold the certificate and also require the designation of a local agent or authorized representative. If the agent is changed during the approval process, transfer of certificate control introduces additional change procedures.

Step 4: Assess reusability of existing documentation. NMPA registration dossiers, CE technical documentation, FDA 510(k) or PMA materials, ISO 13485 and MDSAP certificates are foundational assets, but they must be reorganized according to the target country’s format. For example, some countries require full translation of documents into the local language, while others accept English but require the use of their specified templates.

Step 5: Confirm post-market maintenance requirements. Registration is not the endpoint. Renewals, change notifications, adverse event reporting, and annual updates all consume resources. If these tasks are not pre-planned, the next registration timeline will be dragged down by unresolved issues from earlier phases.

Documentation and Evidence

Technical documentation is the core of the registration review, and the most common issue is insufficient evidence. Biocompatibility is completed according to the ISO 10993 series, but dental materials often require additional oral mucosal irritation and sensitization tests. If only basic cytotoxicity tests are submitted, the review body will request additional testing.

Performance verification must be designed according to the intended use of the product. Dental implants require mechanical fatigue testing and osseointegration-related studies; dental CAD/CAM restorations require verification of marginal fit and fracture resistance. If test standards and methods recognized by the target country are lacking, the number of correction requests will increase.

The risk management report should not merely replicate the ISO 14971 checklist; it needs to incorporate analyses of clinical use scenarios, such as abnormal implant insertion torque and high-speed handpiece heating. If risk management and performance verification are not closed-loop, the review body will question the effectiveness of risk control measures.

The justification for clinical evaluation exemption must be checked item by item against the target country’s regulations. Under the EU MDR, simple exemptions are no longer accepted for some dental devices; clinical literature or clinical data are required. Most Southeast Asian countries require the submission of a clinical evaluation report according to the local document checklist. Even if data from similar products are cited, the literature search strategy and equivalence argument must be described.

Labels and instructions for use are a hidden cause of delays. Some countries require the local language and inclusion of specific warning symbols, storage conditions, shelf life, and material composition labeling. If the translation quality is poor or the labeling required by local regulations is missing, the registration will be returned for modification before further review.

Documents such as the local agent’s declaration of responsibility, certification of free sale certificates, and notarization of authorization letters are also often missing. This is especially true in Middle Eastern and Latin American countries, where notarization and consular legalization have strict procedures. Failure to arrange these in advance can cause delays of several months.

Common Errors

• Incorrect risk classification, submitting a high-risk product via a low-risk pathway, and after rejection having to completely re-prepare the entire documentation set.
• Ignoring technical standard differences between the target country and NMPA/CE/FDA, directly translating existing reports, resulting in a format that does not meet authority requirements.
• Incomplete biocompatibility testing, not selecting the longest contact period based on oral exposure time for dental devices.
• Hasty citation of literature for clinical evaluation without building a traceable evidence chain, leading to doubts about the adequacy of equivalence justification.
• Labels and instructions for use translated literally without localization adjustments, causing return and revision.
• Inappropriate selection of local agent, where the agent is unfamiliar with the registration process and communicates slowly with the review authority.
• Failure to plan for renewal and changes in advance; starting the renewal application only before the current certificate expires, affecting market access continuity.
• Absence of unified version control for multi-country submissions, resulting in inconsistent document content across countries and confusion during corrections.

Company Preparation Checklist

• Establish a product classification and registration pathway assessment table that covers the target country’s regulatory requirements, risk classification, and applicant requirements.
• Inventory existing test reports and certificates, marking validity dates, test standards, and scope of recognition to assess reusability.
• Develop a supplementary testing plan, prioritizing dental-device-specific performance testing and additional biocompatibility tests.
• Create technical document templates, adjust to the CTD or eSTAR format as required by the target country, and unify document numbering.
• Prepare a risk management report and establish a cross-reference table linking each risk control measure to corresponding verification evidence.
• Draft a clinical evaluation plan that clearly defines the literature search strategy, criteria for establishing equivalence with similar products, and the basis for exemption.
• Commission professional translation for labels and instructions for use, and engage a local regulatory consultant to review regulatory compliance.
• Appoint a local agent/authorized representative, sign an agreement, and clarify responsibilities for change notification and adverse event reporting.
• Reserve at least 6 months for post-market maintenance, and include renewal, annual updates, and product changes in the project plan.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgment made by companies is to think registration is simply “submitting documents” and to concentrate all work in the month before submission. The result is that the correction period far exceeds expectations. The correct approach is to clarify the target country’s regulatory pathway and evidence gaps at the start of the project, rather than developing the product first and considering registration later.

At an early stage, companies should perform a gap analysis, compare existing documentation with target-country requirements, and list the tests and documents that must be added. The earlier this step is completed, the more controllable the subsequent timeline will be.

Reusable documentation includes ISO 13485 system certificates, complete biocompatibility reports compliant with ISO 10993, and performance test data compliant with IEC 60601 or ISO 7405. Content that must be localized includes labels and instructions for use, local agent agreements, epidemiological data citations in risk management and clinical evaluation, and post-market surveillance plans.

The local agent is not only responsible for submission but also carries legal responsibilities such as notification of quality system inspections, adverse event reporting, and certificate renewal. If the agent lacks capability or is changed frequently, control of the certificate may be put at risk, leading to termination of registration or invalidation of the certificate. Companies should treat the agent as a long-term partner, not a one-time channel.

To reduce the risk of rework and corrections in multi-country registration, it is best to adopt a structure of a core technical document plus country-specific difference modules. The same clinical evaluation, risk management, and product test reports should be prepared as a traceable master document, with localized appendices added for each country. This maintains content consistency and facilitates responses to the specific requirements of different review bodies.

Finally, the registration timeline is not solely the responsibility of the regulatory affairs team. Senior management should treat registration as a strategic project and allocate resources accordingly; otherwise, no matter how professional the consulting firm, the authority’s review time cannot be compressed.

Frequently Asked Follow-ups

What additional clinical data are required for dental implant registration in Southeast Asian countries?

Most Southeast Asian countries follow the GHWP framework but still require a clinical evaluation report. For implants, a systematic literature search and at least one controlled clinical study are usually required. If data from similar products are cited, device equivalence must be justified. Some countries also require post-market clinical follow-up conducted by a local clinical trial institution, which can add about 6 months to the timeline.

Why does registration in Saudi Arabia take a long time even with a CE certificate?

The Saudi SFDA requires that the ISO 13485 certificate be issued by a certification body recognized by the SFDA, and also requires an MDSAP certificate or an SFDA on-site audit. CE technical documentation cannot be directly converted to SFDA format; it must be re-edited to comply with national guidelines, and product test reports must be submitted. In addition, Saudi Arabia requires the use of an SFDA-recognized local authorized representative, and the registration process may involve Arabic summaries of technical documentation and label review.

Is there a limit on the number of corrections for dental device registration? How long does each correction take?

Most countries do not set an explicit upper limit on the number of corrections, but each correction resets the review clock. For example, Mexico’s COFEPRIS will re-queue the application after receiving correction documentation, and the wait time may be as long as 3 to 6 months. Brazil’s ANVISA imposes strict formal review on corrections and supplementary information; inconsistencies can lead to resubmission. Companies should strive for completeness and accuracy at the time of initial submission and avoid “trial and error” through repeated corrections.

Content Review and Applicability

This article is compiled based on AIMEILI’s registration practice question bank, the medical device international registration knowledge base, and publicly available regulatory information. It is intended for early-stage understanding, document preparation, and project planning, and it does not replace the official requirements of target-country regulatory authorities, testing conclusions, or legal opinions. For specific projects, the latest requirements of the target country’s regulatory authority and the product documentation basis should prevail.